Minerva Neurosciences (NERV) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Spruce Biosciences (SPRB) over the past year, losing 5.6% versus a loss of 74.9%. Over five years, NERV leads with a -76.9% price change compared with -99.8% for SPRB. Spruce Biosciences is the larger company by market cap ($114.0 million vs $112.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | SPRB |
|---|---|---|
| Share price | $2.35 | $39.65 |
| Market cap | $112.21M | $113.95M |
| 1-day change | -2.89% | -4.39% |
| YTD return | -41.54% | -54.48% |
| 1-year return | -5.62% | -74.88% |
| 5-year return | -76.87% | -99.84% |
| Forward P/E | — | 7.97 |
| EPS (TTM) | $-36.12 | $-39.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-293.42M | $-38.97M |
| 52-week high | $12.46 | $154.95 |
| 52-week low | $2.28 | $38.06 |
| Distance from 52-week high | -81.14% | -74.41% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +339.57% | +273.27% |
| Average volume | 181.64K | 78.11K |
| Shares outstanding | 47.75M | 2.87M |
| Employees | 7 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed SPRB by 69.3 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
NERV vs SPRB FAQ
Which is bigger, Minerva Neurosciences or Spruce Biosciences?
Spruce Biosciences (SPRB) is larger, with a market capitalization of $113.95M compared with $112.21M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, NERV or SPRB?
NERV returned -5.62% over the past 12 months, compared with -74.88% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.